Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone plus SGLT2 inhibitors vs SGLT2 inhibitors alone in heart failure (real‑world study)
ChiCTR2500115851Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of finerenone, dapagliflozin, empagliflozin and canagliflozin in heart failure (HF) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Cardiac function evaluation (primary). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
finerenonedapagliflozinempagliflozincanagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2500115851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115851.